Skip to main content
Premium Trial:

Request an Annual Quote

Galapagos Genomics, Euroscreen Form GPCR Collaboration

NEW YORK, Dec. 10 — Galapagos Genomics and Euroscreen, both based in Belgium, have partnered to identify ligands for new GPCRs, the firms said on Monday. The research collaboration will target so-called orphan GPCRs, those GPCRs without known ligands.

 

Using its PhenoSelect expression platform, Galapagos will provide its partner with a library of secreted proteins and peptides, each correlated with a human gene. Euroscreen will screen the compounds for ligands that activate orphan GPCRs with its AequoScreen assay system. Together, the two companies will license validated ligands to pharmaceutical or biotech companies.

 

Financial details of the collaboration were not disclosed.

 

Galapagos Genomics, based in Mechelen, is a privately held functional genomics firm. Its expression platform uses arrayed adenoviruses containing human genes to identify and validate targets.

 

Euroscreen, headquartered in Brussels, was founded as a spin-off of Brussels University in 1994. It is focused on GPCR research and discovery, and has developed a technology to use the jellyfish photoprotein aequorin to identify protein ligands in cell-based assays.

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.